BridgeMD
New treatment option for Colorectal Cancer
Official title MIMICC Study in Patients With Colorectal Cancer
ClinicalTrials.gov ID: NCT07494201
What this study is testing
- What it's testing
- This multicenter prospective interventional study will evaluate stool and saliva microRNA expression and microbiome composition in patients with histologically confirmed colon or rectal cancer during key phases of the diagnostic and therapeutic pathway. The study aims to confirm and refine molecular signatures associated with colorectal cancer, assess the diagnostic and prognostic potential of salivary biomarkers, and characterize dynamic molecular changes during treatment and follow-up
- Time commitment: about 4 months
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Histologically confirmed colon or rectal cancer on endoscopic biopsy
- Any T stage, any N stage, M0-M1, candidate for surgical intervention
- Colon tumors with indication for surgical resection with curative intent, including right hemicolectomy, left hemicolectomy, transverse colon...
- Rectal tumors with indication for upfront surgery or neoadjuvant chemoradiotherapy
- Written informed consent signed before any study procedure
You likely can't join if
- Tis/T1 lesions or lesions almost completely resected by endoscopic polypectomy/EMR/ESD
- Use of immunosuppressive or immunomodulatory drugs within the previous 6 months
- Current or previous diagnosis of other solid or hematologic malignancies
- Inability or refusal to provide informed consent
- Inability or refusal to be followed at the study institution/network
See the full eligibility criteria
- Histologically confirmed colon or rectal cancer on endoscopic biopsy
- Any T stage, any N stage, M0-M1, candidate for surgical intervention
- Colon tumors with indication for surgical resection with curative intent, including right hemicolectomy, left hemicolectomy, transverse colon resection, colectomy, or total proctocolectomy
- Rectal tumors with indication for upfront surgery or neoadjuvant chemoradiotherapy
- Written informed consent signed before any study procedure
- Age between 18 and 75 years
- Tis/T1 lesions or lesions almost completely resected by endoscopic polypectomy/EMR/ESD
- Use of immunosuppressive or immunomodulatory drugs within the previous 6 months
- Current or previous diagnosis of other solid or hematologic malignancies
- Inability or refusal to provide informed consent
- Inability or refusal to be followed at the study institution/network
The study team makes the final eligibility decision.
Where it's taking place
- Candiolo, Torino (TO), Italy
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 4 months per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Candiolo, Torino (TO), Italy. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.